All patients in the cohort were assessed as ER positive luminal breast cancer patients based on conventional pathology diagnostics, but we have shown before that this does not mean that they all had a high ER pathway activity, and that in tumors with low ER activity another signal transduction pathway may be more likely to drive tumor growth [2]. The gene discussed is ESR1; the disease is breast cancer.